sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks Varespladib methyl

Varespladib methyl

CAS No.:
172733-08-3
Catalog Number:
AG00JSBT
Molecular Formula:
C22H22N2O5
Molecular Weight:
394.4205
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
99%
1 week
United States
$557
- +
Product Description
Catalog Number:
AG00JSBT
Chemical Name:
Varespladib methyl
CAS Number:
172733-08-3
Molecular Formula:
C22H22N2O5
Molecular Weight:
394.4205
MDL Number:
MFCD09833542
IUPAC Name:
methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate
InChI:
InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)
InChI Key:
VJYDOJXJUCJUHL-UHFFFAOYSA-N
SMILES:
COC(=O)COc1cccc2c1c(C(=O)C(=O)N)c(n2Cc1ccccc1)CC
UNII:
0NB98NBX3D
Properties
Complexity:
604  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
394.153g/mol
Formal Charge:
0
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
394.427g/mol
Monoisotopic Mass:
394.153g/mol
Rotatable Bond Count:
9  
Topological Polar Surface Area:
101A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.1  
Literature
Title Journal
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovascular drugs and therapy 20120201
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome. Cardiovascular drugs and therapy 20111201
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. European heart journal 20110401
Varespladib. American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Current opinion in lipidology 20101201
Varespladib methyl in cardiovascular disease. Expert opinion on investigational drugs 20101001
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice. Arthritis research & therapy 20090101
Properties